scholarly journals COPD is a Risk Factor for COVID-19, But Does Not Confer Increased Severity of the Disease

Author(s):  
Jae Seok Jeong ◽  
Jong Seung Kim ◽  
Yeon Seok You ◽  
Sang Woo Yeom ◽  
Yong Chul Lee

Abstract Epidemiologic studies suggest that COPD is associated with an increased risk of poor outcome in patients with COVID-19, although they failed to demonstrate COPD as a risk factor for acquiring COVID-19. However, most data have come from a limited global population. In this nationwide cohort study based on the Korean national health insurance claims-based database, COPD is associated with increased risk for COVID-19 and having COPD does not seem to confer substantial risk for severe COVID-19 and mortality. These findings indicate that heterogeneity in the populations across many countries may complicate the net effects of COPD on the COVID-19-related outcomes.

Author(s):  
Da Hye Moon ◽  
Sung Ok Kwon ◽  
Sun-Young Kim ◽  
Woo Jin Kim

Studies have reported associations between long-term exposure to ambient air pollution and lung cancer. However, there have been inconsistent reports of such associations with lung cancer by histological type. Thus, the aim of this study was to assess the association of long-term exposure to particulate matter with an aerodynamic diameter up to 10 μm (PM10) and nitrogen dioxide (NO2) with lung cancer incidence by histological subtype in South Korea. This population-based cohort study included 6,567,909 cancer-free subjects from the Korean National Health Insurance Service (NHIS) database for 2006–2007. We linked population data to Korea Central Cancer Registry data to confirm lung cancer incidence for 2006–2013. Individual exposures to PM10 and NO2 were assessed as five-year average concentrations predicted at subjects’ district-specific home addresses for 2002–2007. We divided these exposures into two categories based on the 75th percentile. Cox proportional hazards models were used to estimate hazard ratios (HRs) of lung cancer incidence for the upper 25% exposure compared to the low 75% by histological subtypes at diagnosis after adjusting for potential confounders. A total of 27,518 lung cancer were found between 2006 to 2013. The incidence of lung cancer was higher in males, smokers, drinkers and subjects with chronic obstructive pulmonary disease. Overall, we did not find an increased risk of lung cancer with higher exposure to PM10 or NO2. However, high exposure to PM10 was associated with increased risk of adenocarcinoma in comparison with lower exposure in males and current smokers (HR, 1.14; 95% CI, 1.03–1.25). This study showed that long-term air pollution exposures were associated with an elevated risk of lung adenocarcinoma in male smokers in Korea.


2021 ◽  
pp. annrheumdis-2021-220439
Author(s):  
Ruriko Koto ◽  
Akihiro Nakajima ◽  
Hideki Horiuchi ◽  
Hisashi Yamanaka

ObjectivesIn patients with gout, treating to target serum uric acid levels (sUA) of ≤6.0 mg/dL is universally recommended to prevent gout flare. However, there is no consensus on asymptomatic hyperuricaemia. Using Japanese health insurance claims data, we explored potential benefits of sUA control for preventing gout flare in subjects with asymptomatic hyperuricaemia.MethodsThis retrospective cohort study analysed the JMDC Claims Database from April 2012 through June 2019. Subjects with sUA ≥8.0 mg/dL were identified, and disease status (prescriptions for urate-lowering therapy (ULT), occurrence of gout flare, sUA) was investigated for 1 year. Time to first onset and incidence rate of gout flare were determined by disease status subgroups for 2 years or more. The relationship between gout flare and sUA control was assessed using multivariable analysis.ResultsThe analysis population was 19 261 subjects who met eligibility criteria. We found fewer occurrences of gout flare, for both gout and asymptomatic hyperuricaemia, in patients who achieved sUA ≤6.0 mg/dL with ULT than in patients whose sUA remained >6.0 mg/dL or who were not receiving ULT. In particular, analysis by a Cox proportional-hazard model for time to first gout flare indicated that the HR was lowest, at 0.45 (95% CI 0.27 to 0.76), in subjects with asymptomatic hyperuricaemia on ULT (5.0<sUA ≤ 6.0 mg/dL), compared with untreated subjects (sUA ≥8.0 mg/dL).ConclusionsOccurrences of gout flare were reduced by controlling sUA at ≤6.0 mg/dL in subjects with asymptomatic hyperuricaemia as well as in those with gout.Trial registration numberUMIN000039985.


Cephalalgia ◽  
2013 ◽  
Vol 34 (5) ◽  
pp. 327-335 ◽  
Author(s):  
Knut Hagen ◽  
Eystein Stordal ◽  
Mattias Linde ◽  
Timothy J Steiner ◽  
John-Anker Zwart ◽  
...  

Background Headache has not been established as a risk factor for dementia. The aim of this study was to determine whether any headache was associated with subsequent development of vascular dementia (VaD), Alzheimer’s disease (AD) or other types of dementia. Methods This prospective population-based cohort study used baseline data from the Nord-Trøndelag Health Study (HUNT 2) performed during 1995–1997 and, from the same Norwegian county, a register of cases diagnosed with dementia during 1997–2010. Participants aged ≥20 years who responded to headache questions in HUNT 2 were categorized (headache free; with any headache; with migraine; with nonmigrainous headache). Hazard ratios (HRs) for later inclusion in the dementia register were estimated using Cox regression analysis. Results Of 51,383 participants providing headache data in HUNT 2, 378 appeared in the dementia register during the follow-up period. Compared to those who were headache free, participants with any headache had increased risk of VaD ( n = 63) (multivariate-adjusted HR = 2.3, 95% CI 1.4–3.8, p = 0.002) and of mixed dementia (VaD and AD ( n = 52)) (adjusted HR = 2.0, 95% CI 1.1–3.5, p = 0.018). There was no association between any headache and later development of AD ( n = 180). Conclusion In this prospective population-based cohort study, any headache was a risk factor for development of VaD.


Sign in / Sign up

Export Citation Format

Share Document